U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H26N2O6
Molecular Weight 438.473
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SUXIBUZONE

SMILES

CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=ONWXNHPOAGOMTG-UHFFFAOYSA-N
InChI=1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)

HIDE SMILES / InChI

Molecular Formula C24H26N2O6
Molecular Weight 438.473
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/23959620

In 2012, two newly developed active pharmaceutical ingredients for horses and food producing animals were released on the German market for veterinary drug products. Those are the parenterally applicable first generation cephalosporin Cefalonium (Cepravin) and the nonsteroidal anti-inflammatory drug Suxibuzone (Danilon). Suxibuzone is a d drug for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation. It is a prodrug of the phenylbutazone, which inactivates prostaglandin H synthase and prostacyclin synthase

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O19183
Gene ID: 791253.0
Gene Symbol: PTGS2
Target Organism: Equus caballus (Horse)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Danilon

Approved Use

Danilon Equidos is a non-steroidal anti-inflammatory drug for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.
Palliative
Danilon

Approved Use

Danilon Equidos is a non-steroidal anti-inflammatory drug for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.
Palliative
Danilon

Approved Use

Danilon Equidos is a non-steroidal anti-inflammatory drug for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.
PubMed

PubMed

TitleDatePubMed
Promotion of hepatocarcinogenesis by suxibuzone in rats initiated with 3'-methyl-4-dimethylaminoazobenzene.
1987 Jul
Evaluation of the palatability of three nonsteroidal antiinflammatory top-dress formulations in horses.
2008 Summer
Effects of top-dress formulations of suxibuzone and phenylbutazone on development of gastric ulcers in horses.
2009 Fall
Rapid confirmatory analysis of non-steroidal anti-inflammatory drugs in bovine milk by rapid resolution liquid chromatography tandem mass spectrometry.
2009 Nov 13
Multicentre, controlled, randomised and blinded field study comparing efficacy of suxibuzone and phenylbutazone in lame horses.
2009 Sep
Antemortem diagnosis of a distal axonopathy causing severe stringhalt in a horse.
2010 Jan-Feb
Patents

Patents

Sample Use Guides

In Vivo Use Guide
for horses: For a 480 kg horse: administer 2 sachets twice daily for 2 days (equivalent to 12.5 mg suxibuzone/kg/day). Follow by administering 1 sachet twice daily for 3 days (equivalent to 6.25 mg suxibuzone/kg/day). Ponies: For a 240 kg pony: administer 1 sachet daily for 2 days (equivalent to 6.25 mg of suxibuzone/kg/day).
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:02:42 UTC 2023
Edited
by admin
on Fri Dec 15 16:02:42 UTC 2023
Record UNII
86TDZ5WP2B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SUXIBUZONE
EP   INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
SUXIBUZONE [MART.]
Common Name English
NSC-757866
Code English
SUXIBUZONE [JAN]
Common Name English
SUXIBUZONE [EP MONOGRAPH]
Common Name English
Suxibuzone [WHO-DD]
Common Name English
SUXIBUZONE [EP IMPURITY]
Common Name English
suxibuzone [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QM02AA22
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
WHO-VATC QM01AA90
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
WHO-ATC M02AA22
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID6021296
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
DRUG CENTRAL
2547
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
EVMPD
SUB10789MIG
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
MESH
C003371
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
CHEBI
32173
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
MERCK INDEX
m10409
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY Merck Index
INN
2955
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
WIKIPEDIA
SUXIBUZONE
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
SMS_ID
100000082990
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
CAS
27470-51-5
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
ChEMBL
CHEMBL1414320
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
DRUG BANK
DB13232
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
FDA UNII
86TDZ5WP2B
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
NCI_THESAURUS
C73095
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
PUBCHEM
5362
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
ECHA (EC/EINECS)
248-477-6
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
NSC
757866
Created by admin on Fri Dec 15 16:02:42 UTC 2023 , Edited by admin on Fri Dec 15 16:02:42 UTC 2023
PRIMARY
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY